Switching from other GLP-1 receptor agonists to semaglutide - impact on HbA1c and body weight: A model-based approach - Articles - Diabetes + Endocrinology

Glycemic ControlObesity and Bariatric Surgery

A model-based simulation of glycemic control and body weight when switching from semaglutide to 3.0 and 4.5 mg doses of once-weekly dulaglutide

Diabetes Obes Metab

Tham LS, Pantalone KM, Dungan K, Munir K, Tang CC, Konig M, Kwan AY

doi: 10.1111/dom.14582

Type 2 Diabetes

Impact of disease duration and β-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on GLP-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial

Diabetes Obes Metab.

Del Prato S, Frias JP, Blonde L, Aroda VR, Shehadeh N, Saremi A, Dex T, Niemoeller E, Souhami E, Liu M, Rosenstock J

doi: 10.1111/dom.14068.

Diabetes - GeneralType 2 Diabetes

Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists

Diabetes Res Clin Pract.

Scheen AJ

doi: 10.1016/j.diabres.2017.03.009.

Diabetes - GeneralType 2 DiabetesGlycemic Control

Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor

Diabetes Obes Metab.

De Fronzo RA

doi: 10.1111/dom.12982.

Type 2 Diabetes

Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes. A retrospective multicenter comparative effectiveness study

Diabetes Obes Metab.

Morieri ML, Rigato M, Frison V, Simioni N, D'Ambrosio M, Tadiotto F, Paccagnella A, Lapolla A, Avogaro A, Fadini GP

doi: 10.1111/dom.13840.

COMMENTED

Type 2 Diabetes

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Lancet Diabetes Endocrinol.

Kristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D, Køber L, Petrie MC, McMurray JJV

doi: 10.1016/S2213-8587(19)30249-9.

COMMENTED

Diabetes - GeneralType 2 Diabetes

Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in SUSTAIN 1-5 trials

Diabetes Obes Metab.

Ahrén B, Atkin SL, Charpentier G, Warren ML, Wilding JP, Birch S, Holst AG, Leiter LA

doi: 10.1111/dom.13353.

Diabetes - GeneralType 2 DiabetesDiabetic Complications

Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy

Diabetes Care.

Douros A, Filion KB, Yin H, Yu OH, Etminan M, Udell JA, Azoulay L

doi: 10.2337/dc17-2280.

COMMENTED

Type 2 Diabetes

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

Lancet.

Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z, Robins D, Haupt A

doi: 10.1016/S0140-6736(18)32260-8.

Related content

A model-based simulation of glycemic control and body weight when switching from semaglutide to 3.0 and 4.5 mg doses of once-weekly dulaglutide

Impact of disease duration and β-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on GLP-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial

Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists

Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor

Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes. A retrospective multicenter comparative effectiveness study

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in SUSTAIN 1-5 trials

Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial